Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
A phase 1/2 trial of Dual-target CAR-NK cells in HER2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.
Overview
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC is a phase 1/2 interventional study registered as NCT07510802 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: Dual-target CAR-NK cells and Lymphodepleting.
Similar pages
not linked directly; found by shared links- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.